Case study: Ego Pharmaceuticals
Established in Melbourne in 1953, Ego Pharmaceuticals is the largest Australian owned pharmaceutical company specialising in dermatology. It employs 545 staff globally with 397 based in Melbourne. Ego exports to 23 countries, with exports making up 43 per cent of the company's net sales. Ego began exporting in 1962 to New Zealand, and today exports to 27 nations throughout Asia Pacific, the Middle East and Europe. Export now makes up 40 per cent of net sales and will continue to be a major driver of growth.
From its world-class facilities in Melbourne the company researches, manufactures and markets over 120 products which treat and prevent skin conditions and maintain healthy skin. Ego's iconic Australian brands include QV Skincare, Sunsense sunscreen, Aqium Hand Sanitiser and Pinetarsol.
Multiple GOVEA Award-winner
Ego Pharmaceuticals was awarded the Victorian Exporter of the Year at the 2016 Governor of Victoria Export Awards and went on to win the Australian Exporter of the year for Health and Biotechnology. It also won the 2015 Governor of Victoria Export Awards Health and Biotechnology Award.
The Export Awards reward Victoria’s most successful and innovative exporters in 15 categories.
Alan Oppenheim, CEO of Ego Pharmaceuticals, said the awards allowed him to showcase the important contribution his staff played in the company’s success.
“It is often difficult to find opportunities to really thank staff and show something that has come from their hard work,” said Alan. “Being able to share these awards with them is invaluable.”
“It is really nice to be able to share both awards with all staff and distributors and give us something to really be proud of.”
Ego has recently established its new global headquarters and warehouse facility at the Logis Estate in Dandenong South. It will undertake infrastructure development at the Logis Estate to support Ego’s 25-year growth requirements.
The headquarters for Ego Pharmaceuticals includes a distribution centre and new manufacturing facility. Stage one of the project was completed in February 2017 and the development is expected to create 200 new jobs.
“This development will enable us to grow exponentially and continue to drive our manufacturing and export business,” said Alan.
“It secures the future of our business in Victoria to continue to grow and innovate as industry leaders to meet the needs of our consumers.”
“We are proud to be driving this growth from Victoria to the world. Australian manufacturing and exporting has significant benefits to the wider economy and we’re committed to continuing to innovate, invest in Australians and lead the industry with our world class practices from state of the art facilities.”
Read more about Ego Pharmaceuticals: 2016 GOVEA exporter of the year.